| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | alectinib (Alecensa®) |
| Formulation | 150 mg capsule |
| Reference number | 2618 |
| Indication | As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/11/2017 |
| NICE guidance | TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |